| Income Statement | 2025-10-31 | |||
|---|---|---|---|---|
| Research and development expenses | 6,683,643 | |||
| General and administrative expenses | 1,639,300 | |||
| Total operating expenses | 8,322,943 | |||
| Operating loss | -8,322,943 | |||
| Financial income, net | 158,646 | |||
| Change in fair value of the warrant liability | 69,201 | |||
| Share of loss on equity investment | -44,830 | |||
| Net loss for the period | -8,278,328 | |||
| Net loss attributable to non-controlling interest | -80,763 | |||
| Net loss for the period attributable to briacell | -8,197,565 | |||
| Net loss per share attributable to briacell - basic | -4.35 | |||
| Net loss per share attributable to briacell - diluted | -4.35 | |||
| Weighted average number of shares used in computing net basic loss per share of common stock | 1,883,906 | |||
| Weighted average number of shares used in computing net diluted loss per share of common stock | 1,883,906 | |||
BriaCell Therapeutics Corp. (BCTXZ)
BriaCell Therapeutics Corp. (BCTXZ)